ADCT - ADC Therapeutics SA
NYSE
->
Healthcare
->
Biotechnology
Epalinges,
Switzerland
Type: Equity
ADCT price evolution
ADCT
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $24.03 | $22.87 | $23.19 | $25.18 |
| Inventory | $16.07 | $15.19 | $16 | $16.18 |
| Total current assets | $333 | $355.36 | $290.21 | $336.29 |
| Long term investments | ||||
| Property, plant & equipment | $14.91 | $15.17 | $15.84 | $16.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $349.08 | $371.78 | $307.97 | $354.78 |
| Current liabilities | ||||
| Accounts payable | $14.37 | $10.71 | $14.31 | $15.57 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $67.68 | $57.63 | $62.98 | $67.67 |
| Long term debt | $436.81 | $429.88 | $423.24 | $426.48 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $521.02 | $503.45 | $502.42 | $503.03 |
| Shareholders' equity | ||||
| Retained earnings | -$1462.59 | -$1418.62 | -$1382.08 | -$1335.47 |
| Other shareholder equity | $0.2 | -$0.34 | -$0.2 | -$148.25 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $466.54 | $439.19 | ||
| Short term investments | ||||
| Net receivables | $25.18 | $74.35 | $31.04 | $1.7 |
| Inventory | $16.18 | $18.56 | $11.12 | |
| Total current assets | $336.29 | $446.01 | $525.18 | $450.45 |
| Long term investments | $41.24 | $47.91 | ||
| Property, plant & equipment | $16.13 | $9.98 | $11.23 | $4.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63.24 | |||
| Total investments | ||||
| Total assets | $354.78 | $529.17 | $617.97 | $513.69 |
| Current liabilities | ||||
| Accounts payable | $15.57 | $12.35 | $12.08 | $5.28 |
| Deferred revenue | ||||
| Short long term debt | $13.39 | $3.63 | ||
| Total current liabilities | $67.67 | $98.96 | $73.94 | $40.44 |
| Long term debt | $426.48 | $316.16 | $305.82 | $34.77 |
| Total noncurrent liabilities | $137.75 | |||
| Total debt | ||||
| Total liabilities | $503.03 | $440.44 | $451.88 | $178.19 |
| Shareholders' equity | ||||
| Retained earnings | -$1335.47 | -$925 | -$924.88 | -$694.86 |
| Other shareholder equity | -$148.25 | -$0.36 | $102.83 | $43 |
| Total shareholder equity | $166.09 | $335.5 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $18.46 | $17.41 | $16.79 | |
| Cost of revenue | ||||
| Gross Profit | $17.61 | $16.19 | $15.57 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $53.18 | $45.23 | $55.55 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.09 | $0.23 | $43.17 | |
| Interest expense | -$8.53 | -$7.25 | -$9.62 | |
| Net income | ||||
| Net income | -$43.97 | -$36.54 | -$85.03 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $69.56 | $209.91 | ||
| Cost of revenue | $141.82 | |||
| Gross Profit | $67.03 | $207.83 | -$141.82 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $77.23 | |||
| Total operating expenses | $233.01 | $328.73 | $219.05 | |
| Operating income | -$219.05 | |||
| Income from continuing operations | ||||
| EBIT | -$219.05 | |||
| Income tax expense | $39.11 | $1.14 | $0.33 | |
| Interest expense | -$35.78 | $8.01 | -$4.93 | |
| Net income | ||||
| Net income | -$240.05 | -$155.8 | -$246.29 | |
| Income (for common shares) | -$246.29 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.78 | -$0.56 | -$0.53 | -$3.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $98.17 | $99.05 | $0.36 | $73.88 |
| Effect of exchange rate | $0.26 | -$0.03 | -$0.04 | $0.18 |
| Change in cash and equivalents | -$4.33 | $21.52 | -$44.31 | -$47.84 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$230.03 | -$246.29 | ||
| Operating activities | ||||
| Depreciation | $2.55 | $1.93 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$233.38 | -$168.73 | ||
| Investing activities | ||||
| Capital expenditures | -$3.43 | -$0.8 | ||
| Investments | ||||
| Total cash flows from investing | -$3.22 | -$2.51 | -$6.67 | -$2.83 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $48.61 | $61.75 | ||
| Total cash flows from financing | $73.88 | -$0.59 | $267.39 | $494.97 |
| Effect of exchange rate | $0.18 | -$0.21 | $0.01 | $0.23 |
| Change in cash and equivalents | -$47.84 | -$140.1 | $27.35 | $323.64 |
News
Fundamentals
| Market cap | $395.45M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 96.69M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 27.40% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.92 |
| Quick ratio | 4.68 |